3-(3-(4-(3-(furan-2-yl)acryloyl)phenoxy)propyl)-1-methyl-1H-imidazol-3-ium bromide

ID: ALA5205237

PubChem CID: 132277793

Max Phase: Preclinical

Molecular Formula: C20H21BrN2O3

Molecular Weight: 337.40

Names and Identifiers

Canonical SMILES:  Cn1cc[n+](CCCOc2ccc(C(=O)/C=C/c3ccco3)cc2)c1.[Br-]

Standard InChI:  InChI=1S/C20H21N2O3.BrH/c1-21-12-13-22(16-21)11-3-15-25-19-7-5-17(6-8-19)20(23)10-9-18-4-2-14-24-18;/h2,4-10,12-14,16H,3,11,15H2,1H3;1H/q+1;/p-1/b10-9+;

Standard InChI Key:  VJWCVTSYLOQJPZ-RRABGKBLSA-M

Molfile:  

     RDKit          2D

 26 27  0  0  0  0  0  0  0  0999 V2000
   -3.3586    0.3570    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
    0.0427    0.4972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7572    0.9095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4691    0.4977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4691   -0.3274    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7591   -0.7392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0427   -0.3312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1838    0.9102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1838    1.7355    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.8984    0.4977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6131    0.9102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3277    0.4977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0423    0.9102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6609    0.3389    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3304   -0.3956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5062   -0.3032    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6717   -0.7437    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3865   -0.3312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1011   -0.7437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8158   -0.3312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5304   -0.7437    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6166   -1.5640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.4234   -1.7355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.8358   -1.0212    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2839   -0.4082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6609   -1.0212    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  3  2  2  0
  4  3  1  0
  5  4  2  0
  6  5  1  0
  2  7  1  0
  7  6  2  0
  4  8  1  0
  8  9  2  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 13 12  2  0
 13 14  1  0
 14 15  2  0
 16 15  1  0
 12 16  1  0
  7 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 22 21  1  0
 22 23  2  0
 23 24  1  0
 24 25  1  0
 25 21  2  0
 24 26  1  0
M  CHG  2   1  -1  21   1
M  END

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 337.40

Molecular Weight (Monoisotopic): 337.1547

AlogP: 3.27

#Rotatable Bonds: 8

Polar Surface Area: 48.25

Molecular Species: NEUTRAL

HBA: 4

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: -0.79

CX LogD: -0.79

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.27

Np Likeness Score: -0.58

References

1. Gupta O, Pradhan T, Bhatia R, Monga V..  (2021)  Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships.,  223  [PMID:34171661] [10.1016/j.ejmech.2021.113606]

Source

Source(1):

• Scientific Literature